RBC Bioscience

RBC Bioscience EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of RBC Bioscience (6848.TWO) as of Nov 5, 2026 is 35.80 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 14.54 M TWD — a change of 146.23% (higher).

EBITDA

35.80 MTWD

YoY

146.23%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of RBC Bioscience is 2024 35.80 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of RBC Bioscience was 2023 14.54 M TWD. It decreases by 146.23% higher compared to the previous year.

The RBC Bioscience EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
14.11 M TWD
Jan 1, 2019
19.52 M TWD
Jan 1, 2020
188.39 M TWD
Jan 1, 2021
48.61 M TWD
Jan 1, 2022
7.75 M TWD
Jan 1, 2023
14.54 M TWD
Jan 1, 2024
35.80 M TWD
The RBC Bioscience EBITDA history
YEAREBITDAYoY
35.80 MTWD+146.23%
14.54 MTWD+87.60%
7.75 MTWD-84.06%
48.61 MTWD-74.20%
188.39 MTWD+865.19%
19.52 MTWD+38.35%
14.11 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of RBC Bioscience is 35.80 M TWD in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of RBC Bioscience changed from 14.54 M TWD to 35.80 M TWD, representing a 146.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s RBC Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — RBC Bioscience

All Key Metrics — RBC Bioscience